



IAP6 Rec'd PCT/PTO 23 FEB 2006 Pct

Docket No.: 64353(70904)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kenji Nakanishi et al.

Application No.: 10/554,301 ✓

Confirmation No.: N/A

Filed: October 24, 2005

Art Unit: N/A

For: INHIBITOR SCREENING METHOD AND
ATOPIC DERMATITIS-LIKE SYMPTOM
INDUCING METHOD WHICH UTILIZES
INDUCTION OF PRODUCTION OF
INTERLEUKIN 18 BY KERATINOCYTE
AND UTILIZATION OF SAME

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 64353(70904). A duplicate copy of this paper is enclosed.

Dated: February 20, 2006

Respectfully submitted,

By 

Jonathan M. Sparks, Ph.D.

Registration No.: 53,624


EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/554,301
				Filing Date	October 24, 2005
				First Named Inventor	Kenji Nakanishi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	64353(70904)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Colin JAMORA and Elaine FUCHS, "Intercellular adhesion, signalling and the cytoskeleton", Nature Cell Biology, 4:E101-E108 (April 2002)		
	CB	A. GRONE, "Keratinocytes and cytokines", Veterinary Immunology and Immunopathology 88:1-12 (2002)		
	CC	K. YAMANAKA et al, "Skin-specific Caspase-1 Transgenic Mice Show Cutaneous Apoptosis and Pre-Endotoxin Shock Condition with a High Serum Level of IL-18.", The Journal of Immunology, pp 997-1003 (2000)		
	CD	H. KONISHI et al, "IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions.", PNAS, Vol.99 No.17, pp11340-11345, August 20, 2002)		
	CE	Yong GU et al, "Activation of Interferon-γ Inducing Factor Mediated by Interleukin-1β Converting Enzyme", SCIENCE, 275:206-209 (1997)		
	CF	H. TSUTSUI et al, "Caspase-1-Independent, Fas/Fas Ligand-Mediated IL-18 Secretion from Macrophages Causes Acute Liver Injury in Mice", Immunity 11:359-367 (1999)		
	CG	E. SEKI et al, "Lipopolysaccharide-Induced IL-18 Secretion from Murine Kupffer Cells Independently of Myeloid Differentiation Factor 88 That Is Critically Involved in Induction of Production of IL-12 and IL-1β ¹ ", The Journal of Immunology, pp2651-2657 (2001)		
	CH	Charles A. DINARELLO, "Interleukin-1β, Interleukin-18, and the Interleukin-1β Converting Enzyme", Annals New York Academy of Sciences, pp1-11 (1998)		
	CI	G. FANTUZZI and C. A. DINARELLO, "Interleukin-18 and Interleukin-1β: Two Cytokine Substrates for ICE (Caspase-1)", Journal of Clinical Immunology, 19(1):1-11 (1999)		
	CJ	H. OKAMURA et al, "Cloning of a new cytokine that induces INF-γ production by T cells.", Nature, 378(6552):88-91 (1995)		
	CK	T. YOSHIMOTO et al, "IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils", PNAS, 96(24):13962-13966 (1999)		
	CL	T. YOSHIMOTO et al, "IL-18 induction of IgE: Dependence on CD4 ⁺ T cells, IL-4 and STAT6" (Nature Immunology, Vol.1 No.2, pp132-137 August 2000)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

530451

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/554,301
				Filing Date	October 24, 2005
				First Named Inventor	Kenji Nakanishi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	1	Attorney Docket Number	64353(70904)

	CM	T. HOSHINO et al, "In vivo administration of IL-18 can induce IgE production though T _H 2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4 ⁺ T cells", Eur. J. Immunol, pp1998-2006 (2000)	
	CN	K. NAKANISHI et al, "INTERLEUKIN-18 REGULATES BOTH TH1 AND TH2 RESPONSES", Annu.Rev. Immunol, pp423-474 (2001)	
	CO	K. THESTRUP-PEDERSEN, "Clinical aspects of atopic dermatitis", Clinical and Experimental Dermatology, 25:535-543 (2000)	
	CP	A. WOLLENBERG et al, "Atopic dermatitis: pathogenetic mechanisms", Clinical and Experimental Dermatology, 25:530-534 (2000)	
	CQ	T. TANAKA et al, "Interleukin-18 Is Elevated in the Sera from Patients with Atopic Dermatitis and from Atopic Dermatitis Model Mice, NC/Nga", Int Arch Allergy Immunol, pp236-240 (2001)	
	CR	T. YOSHIMOTO et al, "Nonredundant Roles for CD1d-restricted Natural Killer T Cells and Conventional CD4 ⁺ T Cells in the Induction of Immunoglobulin E Antibodies in Response to Interleukin 18 Treatment of Mice", The Journal of Experimental Medicine, 197(8):997-1005 (2003)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/554,301

Attorney Docket No.: 64353(70904)

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on February 20, 2006
Date

Sharon Bizokas
Signature

Sharon Bizokas

Typed or printed name of person signing Certificate

@@@
Registration Number, if applicable

(617) 439-4444
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages)
Form PTO/SB/08 (2 pages)
18 References
Return Receipt Postcard